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Abstract 
Effects of spironolactone, losartan and combination 
therapy on diabetic nephropathy in OLETF rats 
 
Myoung Sook Shim 
Dept. of Medical Science 
The Graduate School 
Yonsei University 
 
Backgrounds Although there were some evidences that spironolactone 
could attenuate albuminuria in type 2 diabetes via anti-inflammatory and 
anti-oxidants effects, the effects of spironolactone on VEGF expression 
on kidney in diabetic nephropathy were not elucidated. In this study, we 
examined the effects of spironolactone, losartan, and combination with 
spironolactone and losartan on albuminuria and glomerular VEGF 
expression in type 2 diabetic rat model.  
Methods Thirty-three OLETF rats were divided into the following four 
groups and treated with different medications from 25 weeks to 50 weeks: 
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control OLETF group for diabetic controls (N=5), spironolactone group 
(N=10), losartan group (N=9), and combination group (N=9). At 15, 30, 
and 50 weeks, urine was collected for 24 hours urine protein amounts and 
albumin-creatinine-ratio (ACR). At 50 weeks, all experimental rats were 
sacrificed and both kidneys were prepared for western blot and RT-PCR 
for VEGF, TGF-β, and type IV collagen. 
Results At 50 weeks, ACR was significantly decreased in losartan and 
combination regimen treated group (1.21±0.81, 1.01±0.99, p<0.05) 
compared with that of control OLETF group (4.35±1.19). But, in 
spironolactone treated group, ACR was not decreased. There was a 
significant reduction in glomerular VEGF mRNA levels in spironolactone 
and combination regimen treated group compared with control OLETF 
group. But, western blot did not show significant difference among groups. 
TGF-β and type IV collagen expressions were significantly decreased in 
spironolactone and combination regimen treated groups. MDA levels were 
significantly decreased in combination regimen treated group than that of 
control diabetic rat group. 
Conclusion These results suggest that combination therapy of 
spironolactone and losartan may contribute the beneficial effect on diabetic 
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nephropathy by reducing VEGF, TGF-β, type IV collagen expression and 
oxidative stress in type 2 diabetic rat models. 
-------------------------------------------- 
Key Words: Spironolactone, losartan, diabetic nephropathy, vascular 
endothelial growth factor 
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I. Introduction 
 
It is well known that renin-angiotensin-aldosterone system (RAA 
system) has an important role in cardiovascular disease, diabetic 
nephropathy, and chronic renal disease through a mechanism of inflammation, 
fibrosis, and necrosis(1-5). For these reasons, the angiotensin converting 
enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) are 
established as an effective regimen for chronic heart failure and diabetic 
nephropathy (6-11). 
In the long term use of renin angiotensin system blockade, plasma 
aldosterone levels have been shown to increase in 40% of patients with 
diabetic nephropathy and 20% of patients with chronic renal failure which is 
called aldosterone escape phenomenon (12-13). In these patients, proteinuria-
reducing effects of ACEI and ARB are also decreased (14).  In these aspects, 
a reduction of aldosterone level itself is thought to be an important indicator 
of treatment. 
Recent data showed that aldosterone receptor blocker could reduce 
proteinuria via decreasing various growth factors (15-18). Also, it was 
reported that aldosterone receptor blocker treatment has an additional effect 
on reduction of proteinuria in patients with chronic renal disease who were 
failed to a treatment of ACEI (19). 
Vascular endothelial growth factor (VEGF), one of the strong 
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angiogenetic factors, has been known to have important role in 
neovascularization of atherosclerotic plaque or solid cancers (20-22) and also 
progression of diabetic nephropathy (23). Although it is reported that ARB 
treatment has protective effects on diabetic nephropathy by reducing VEGF 
(24, 25), there is no data about the effect aldosterone receptor blocker on renal 
VEGF expression. 
In this study, we investigated the effects of losartan, spironolactone 
and their combination treatment on proteinuria and renal VEGF expression in 
type 2 diabetic rat model. 
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II. Materials and Methods 
 
1. Animals and drugs 
Thirty-three male Otsuka-Long-Evans-Tokushima-Fatty (OLETF, 
Otsuka Pharmaceutical, Tokushima, Japan) rats were used. They were 
divided into 4 groups at the age of 25 weeks and received spironolactone 
(50mg/kg/day) and losartan (20 mg/kg/day) in drinking water until 50 weeks. 
All rats were given free access to standard rat food and drinking water. 
First is diabetic control OLETF group (CO, N=5), second is spironolactone 
treated diabetic group (SPR, N=10), third is losartan treated diabetic group 
(LO, N=9) and fourth is spironolactone and losartan combination treated 
diabetic group (COM, N=10). The research protocol was approved by the 
animal ethics committee of the Yonsei University Wonju College of Medicine 
(Wonju, Korea). 
 
2. Basal parameters 
At the age of 15, 30, 40, 50 weeks, body weights and blood glucose 
(SurestepR, Lifescan Inc, MA, USA) were checked. Blood pressure was 
examined by using tail-cuff plethysmography at 30, 40, 50 weeks. Twenty 
four hour urine was collected at 15, 25, 30, 50 weeks for measuring urine 
protein amounts (Roche Molecular Biochemicals, Indianapolis, IN) and 
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albumin-creatinine ratio (ACR) by ELISA (Shibayagi, Shibukawa, Japan) 
method. 
 
3. Kidney extraction 
At 50 weeks, all experimental rats were sacrificed under anesthesia by 
intraperitoneal injection of ketamine (70 mg/kg). One kidney was preserved 
using a quick freeze method with liquid nitrogen while the contralateral 
kidney was fixed in 4% paraformaldehyde for 48 hours, and then embedded 
in paraffin for histological examination and immunohistochemical staining of 
VEGF. Right kidneys were rapidly frozen by liquid nitrogen and stored at -
70℃ for western blotting and real time RT PCR. 
 
4. Kidney histologic examination 
Paraffin-embedded kidney tissues were cut into 7μm-thick slices and 
stained with periodic acid-Schiff (PAS). Glomerular matrix index (GMI) 
score was measured for glomerulosclerosis. The severity of sclerosis for 
each glomerulus was graded from 0 to 4 as follows (26): Grade 0, normal; 
grade 1, mild sclerosis (less than 25% of glomerulus); grade 2, moderate 
sclerosis (25~50% of glomerulus); grade 3, moderate-severe sclerosis 
(50-75% of glomerulus); grade 4, severe sclerosis (75~100% of 
glomerulus) and for each rat no less than 20 glomeruli were analyzed in each 
kidney section. 
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5. Immunohistochemical stain of VEGF 
 The kidney tissues were fixed in 4% paraformaldehyde and 
subsequently embedded in paraffin. Serial 7μm-thick sections were 
obtained and fixed on the slides. The sections were deparaffinized for 
immunohistochemical stain. Then slides were transferred to 10-mmol/L 
citrated buffer solution (pH 6.0) and washed with distilled water and then 
0.05% H2O2-methanol was applied for 15 min, after that added 1
st antigen 
1:1000 monoclonal anti-VEGF antibody (Santa Cruz Biotechnology Inc., SC, 
USA) at room temperature. Next, biotinylated secondary antibody in rat ABC 
staining system (Santa Cruz Biotechnology Inc., SC, USA) was added, and 
then avidin and biotinylated horseradish peroxidase (ABC reagents) are also 
added. At last, the slides were incubated in peroxidase substrates containing 
0.05% 3, 3’-diaminobenzidine tetrahydrochloride (DAB). Stained tissues 
were observed under light microscope with charged-coupled devices camera 
(Pulnix, MA, USA), glomerular images were sent to computer monitor and 
then VEGF optical densities were measured by image analyzer. 
 
6. Real time RT-PCR  
Total RNA was extracted from the kidney tissues which stored at -
70℃ by snap-frozen in liquid nitrogen with TRIzol LS reagent (GIBCO BRL, 
USA) and total RNA was reverse transcribed into cDNA using oligo-(dT) 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
- 6 - 
 
primer (Promega, Madison, WI, USA). 
The real-time RT-PCR was performed by using SYBR Green RT-
PCR kit (Qiagen, Valencia, CA) and measured with Roter-Gene RG-3000 
cycler (Corbett Research, Mortlake, NSW, Australia). Primer oligonucleotide 
sequences for VEGF, TGF-β, collagen type IV and GAPDH are as follows. 
VEGF forward; 5’-GTATATCTTCAAGCCGTCCTGTGTG-3’  
VEGF reverse; 5’-GATCCGCATGATCTGCATAGTGAC-3’  
TGF-β forward; 5’-TGAGTGGCTGTCTTTTGACG-3’ 
TGF- β reverse; 5’-TGGGACTGATCCCATTGATT-3’ 
Collagen type IV forward; 5’-CCAGGATTCCAAGGTCAGAA-3’ 
Collagen type IV reverse; 5’-CCCTGGTTCTCCTTTGATGA-3’ 
GAPDH forward; 5’-TCAGGTCATCACTATCGGCAATG-3’  
GAPDH reverse; GGAATTGAATGTAGTTTCATGGATGC-3’ 
The real-time RT-PCR was performed by running for 10 min at 95℃, 
subsequently, 40 cycles that consisting of denaturation for 15s at 94℃, 
annealing for 30s at 58℃ and extension 30s at 72℃ were applied. After that 
rinse and melting process were applied, detection of fluorescent products 
was done at 92℃ extension. The cycle threshold (△Ct = Ct VEGF - Ct β-actin) 
of each samples were calculated and the relative change ratio was calculated 
using VEGF/β-actin mRNA ratio. 
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7. Western blot analysis 
The cortex of each kidney was homogenized in RIPA buffer and the 
lysates were incubated in ice for 20 min and then centrifuged at 15,000 rpm 
to remove cellular debris. 10 ㎍ of proteins were electrophoresesed on 10% 
SDS-PAGE gels at 100V. Proteins were transferred to Polyvinylidene 
fluoride PVDF membrane for 1h at 280mA in Tris-based buffer. Non-
specific binding sites were blocked with 5% non-fat dried milk for 1h and 
membranes incubated anti-rat beta actin (1:2000 dilution; Cell signaling, 
USA) or VEGF antibody (1:1000 dilution; R&D System, Minneapolis, USA) 
for overnight. Antibody-treated membranes were visualized by the ELC 
Western Blotting Analysis System (Amersham Biosicences, Buckinghamshire, 
UK) with anti-rabbit IgG or anti-goat IgG-HRP antibody. 
 
8. MCP-1 and MDA 
MCP-1 levels as inflammatory marker were measured in 24 hours 
urine by quantitative sandwich ELISA kit (Biosource Inc., CA, USA) (29) and 
MDA(Malonyldialdehyde) as oxidative stress marker were measured by 
fluorometric HPLC method. 
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9. Statistical analysis 
All data are presented as means ± SD. Oneway ANOVA, Turkey test 
(multiple comparisons) windows SPSS 12.0 was used for statistical analysis.  
Western blot results were revised by beta actin then used Kruskall-Wallis 
test and Mann-Whitney test.  P< 0.05 was considered to be statistically 
significant. 
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II. Results 
1. Changes of body weight, blood glucose and blood 
pressure 
There were no differences in body weights and plasma glucose levels 
at each age. But, blood pressure levels of LO and COM group at 40 weeks, 
and COM group at 50 weeks were significantly lower than that of CO group 
(Table 1). 
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Table 1. Characteristics of experimental rats 
 
 15 wks 30 wks 40 wks 50 wks 
Body weights (g) 
CO 554.60±105.06 608.00±45.49 574.00±25.09 602.00±46.04 
SPR 489.30±40.27 589.90±74.11 585.70±76.49 596.00±80.71 
LO 450.11±32.67* 554.56±65.45 558.11±80.21 580.56±97.45 
COM 465.11±68.46 570.78±86.22 562.33±66.40 577.22±78.54 
Blood glucose (mg/dL) 
CO 113.82±17.02 140.20±17.41 123.20±19.86 140.80±20.29 
SPR 118.60±17.01 137.60±18.07 122.70±16.58 146.60±35.30 
LO 107.56±12.69 144.00±21.14 113.89±13.10 123.67±16.90 
COM 119.89±18.08 136.67±12.67 123.89±18.63* 127.69±16.88 
Blood pressure (mmHg) 
CO  117.60±4.75 135.94±9.17 132.11±10.26 
SPR  116.40±9.01 123.79±5.85 132.11±13.23 
LO  123.19±6.19 116.76±12.20* 131.02±8.19 
COM  117.38±6.71 115.61±12.74* 109.30±10.24* 
 
Data are represented by mean ± SD. *: p<0.05 compared with CO group.  
CO, control OLETF group; SPR, spironolactone treated OLETF group; LO, losartan 
treated OLETF group; COM, spironolactone and losartan treated OLETF group. 
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2. 24 hours urine protein amounts and albumin-creatinine 
ratio (ACR) 
At 15 and 30 weeks, there were no differences in 24 hours urine 
protein amounts and ACR among all groups. At 50 weeks, LO and COM 
groups showed significant decrease in 24 hours urine protein amounts and 
ACR, but SPR group could not show the reduction of proteinuria and ACR 
compared with CO group (Table 2). 
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Table 2. Changes in ACR and 24-hour urine protein amounts 
 15 wks 30 wks 50 wks 
ACR (mg/mgCr) 
CO 0.50 ± 0.13 1.01 ± 0.96 4.35 ± 1.19 
SPR 0.39 ± 0.31 0.93 ± 0.62 3.26 ± 1.74 
LO 0.26 ± 0.14 0.82 ± 0.81 1.21 ± 0.81* 
COM 0.43 ± 0.11 0.96 ± 0.95 1.06 ± 0.98* 
24 hr urine protein levels (mg/day) 
CO 4.67 ± 1.26 34.47 ± 12.22 77.04 ± 23.57 
SPR 11.29 ± 7.68 30.64 ± 28.42 70.24 ± 38.84 
LO 10.49 ± 4.71 27.91 ± 23.99 29.23 ± 22.14* 
COM 9.61 ± 4.03 26.15 ± 21.90 21.77 ± 11.34* 
 
Data are represented by mean ± SD. *: p<0.05 compared with CO group.  
CO, control OLETF group; SPR, spironolactone treated OLETF group; LO, losartan 
treated OLETF group; COM, spironolactone and losartan treated OLETF group 
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3. PAS staining of glomeruli and glomerular matrix index 
(GMI) score 
Glomerular mesangial expansion was observed in CO group compared 
with other groups in PAS staining of glomeruli (Fig. 1-A). 
Glomerular matrix index (GMI) scores were significantly decreased in 
all medication treatment groups compared with CO group. Also, COM group 
showed marked decrement of GMI scores than those of SPR and LO groups 
(Fig. 1-B). 
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B. 
 
 
Figure 1. PAS staining of glomeruli (A) and glomerular matrix indices (GMI) 
(B). PAS staining of glomeruli showed marked mesangial expansion and 
sclerosis in CO group compared with other groups. Compared with CO group, 
GMI scores were significantly decreased in SPR, LO, and COM groups. CO, 
control OLETF group; SPR, spironolactone treated OLETF group; LO, 
losartan treated OLETF group; COM, spironolactone and losartan treated 
OLETF group. *: p<0.05 compared with CO group. †: p<0.05 compared with 
SPR group. ‡: p<0.05 compared with LO group. Scale bar, 100 ㎛. 
 
 
* 
* 
*,†,‡ 
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4. Immunohistochemical staining for VEGF  
Immunohistochemical staining for glomerular VEGF revealed a clear 
increase in VEGF expression in the CO group compared with all medication 
treated groups (Fig. 2-A). The optical density of immunohistochemical 
staining for VEGF in the LO and COM groups were significantly increased 
compared with CO group. But SPR group showed no difference compared 
with CO group (Fig. 2-B). 
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A. 
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B. 
 
 
Figure 2. Immunohistochemical staining (A) and optical densities (B) for 
glomerular VEGF. Compared with LO and COM groups, darker pigmentation 
of glomeruli was shown in CO and SPR group. Optical densities of glomerular 
VEGF in LO and COM groups were significantly lower than those of CO and 
SPR groups. CO, control OLETF group; SPR, spironolactone treated OLETF 
group; LO, losartan treated OLETF group; COM, spironolactone and losartan 
treated OLETF group. *: p<0.05 compared with CO group. Scale bar, 100 ㎛. 
 
 
 
 
* * 
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5. Real time RT-PCR for VEGF, TGF-β, type IV collagen  
Quantitative analysis revealed that VEGF mRNA expression was 0.61-
fold at SPR group, 0.47-fold at LO group, and 0.63-fold at COM group when 
compared with CO group (Fig. 3). TGF-β mRNA expression was 
significantly decreased in all treatment groups compared to CO group. Also, 
SPR and COM groups showed lower expression of TGF-β mRNA than that 
of LO group (Fig. 4). Type IV Collagen mRNA expression was significantly 
decreased in SPR and COM groups compared with CO group (Fig. 4). 
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Figure 3. VEGF mRNA expression by real-time RT-PCR. Quantitative 
analysis revealed that expression of VEGF mRNA was 0.61-fold at SPR 
group, 0.47-fold at LO group, and 0.63-fold at COM group when compared 
with CO group. CO, control OLETF group; SPR, spironolactone treated 
OLETF group; LO, losartan treated OLETF group; COM, spironolactone and 
losartan treated OLETF group. *: p<0.05 compared with CO group.  
 
* 
* 
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Figure 4. TGF-β and collagen type IV mRNA expression by real-time RT-
PCR. Compared with CO group, TGF-β and collagen type IV mRNA 
expression of SPR and COM groups were significantly decreased. CO, control 
OLETF group; SPR, spironolactone treated OLETF group; LO, losartan 
treated OLETF group; COM, spironolactone and losartan treated OLETF 
group. *: p<0.05 compared with CO group, ‡: p<0.05 compared with LO 
group. 
 
 
 
 
 
 
*,‡  *,‡  
*,‡  
*,‡  
* 
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6. Western blot of VEGF protein expression 
Western blot did not show any differences among groups (Fig.5).  
 
 
 
Figure 5. Western blot for renal VEGF expression. Western blot did not show 
any differences among groups.  
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7. MCP-1 and MDA 
At 15 and 50 weeks, 24 hours MCP-1 levels were not different among 
four groups just showing decreasing tendency in COM group (Fig. 6). At 50 
weeks, MDA levels were significantly decreased in COM group compared 
with CO group (Fig. 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PDF created with pdfFactory Pro trial version www.pdffactory.com
  
- 24 - 
 
 
Figure 6. 24 hours urinary MCP-1 levels. MCP-1 levels were not different 
among four groups just showing decreasing tendency in COM group. CO, 
control OLETF group; SPR, spironolactone treated OLETF group; LO, 
losartan treated OLETF group; COM, spironolactone and losartan treated 
OLETF group. 
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Figure 7. 24 hours urinary MDA levels. MDA levels were significantly 
decreased in COM group than that of CO group. CO, control OLETF group; 
SPR, spironolactone treated OLETF group; LO, losartan treated OLETF 
group; COM, spironolactone and losartan treated OLETF group. *: p<0.05 
compared with CO group. 
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IV. Discussion 
We investigated the effects of a combination treatment consisting of 
losartan (angiotensin receptor blocker, ARB) and spironolactone 
(aldosterone receptor blocker) for proteinuria and renal VEGF expression in 
a type 2 diabetic rat model. 
Diabetic nephropathy is the most common cause of end-stage renal 
disease (ESRD) and diabetic ESRD patients are more prone to cardiovascular 
mortality than other caused ESRD patients. Therefore, early identification 
and renoprotective treatment are critical for the prevention of end organ 
damage from diabetic nephropathy (27-28).   
It is well known that treatments with angiontensin converting enzyme 
inhibitor (ACEI) or angiotensin receptor blocker (ARB) could retard the 
progression of diabetic nephropathy, chronic heart failure and chronic renal 
failure through the reduction of blood pressure and anti-inflammatory, anti-
sclerosing effects (6-11). Recent reports indicate that spironolactone, an 
aldosterone receptor blocker, reduces proteinuria by decreasing oxidative 
stress and providing anti-inflammatory effects (16-18, 29, 30). Although 
aldosterone receptor blockers may be useful for the treatment of diabetic 
nephropathy, they could be restrictively used due to hyperkalemia. Saito et 
al and Sepkens et al reported that hyperkalemia exceeding 5.5mEq/L may 
occurred even if the dose of spironolactone is as low as 25 mg. Thus it is 
essential  to monitor serum potassium (31-32). 
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In our data, losartan and combination regimen treated rat groups 
showed significant decreases in 24 hours urine protein amounts and ACR. 
But, spironolactone monotherapy group did not show the significant 
reduction in 24 hours urine protein amounts and ACR. This data may be 
explained by the difference of treatment period of spironolactone. Recent 
studies reported that treatment with aldosterone receptor blockers in the 
early stages of nephropathy may reduce proteinuria, but it has no beneficial 
effects at later stages (33-34). Because we started the spironolactone 
treatment at 25 weeks, effects of spironolactone on diabetic nephropathy 
could be underestimated compared with other studies that initiated the 
treatement at early stage (16).  Another possible explanation is the different 
effects of spironolacone between hemodynamics and fibrosis process. PAS 
staining of glomeruli revealed marked mesangial expansion and sclerosis in 
the diabetic control group compared to other groups. Real time RT-PCR for 
TGF-beta and collagen IV, which are well known factors of renal fibrosis, 
showed decreased levels in the spironolactone treated group and in the 
spironolactone and losartan combination group in agreement with the results 
of previous studies (35-36). But, there were no differences in blood pressure 
between the spironolactone treated group and other groups. That might 
mean that spironolactone could operate the action through non-
hemodynamic mechanism. This phenomenon might imply that proteinuria 
were resulted from different mechanisms from renal fibrosis. Also, 
spironolactone might effects on renal fibrosis but could not effect on  
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hemodynamics in our study (37). 
In diabetic nephropathy, the VEGF expression may be increased by various 
growth factors including platelet derived growth factor (PDGF) and 
accumulation of hyperglycemia-induced advanced glycated end products 
(AGEs) (38-41). Recent studies revealed that ACEI and ARB could be 
decrease the proteinuria by reducing VEGF expression in type 2 diabetic rat 
model (24, 42). In the present study, we compared the glomerular VEGF mRNA 
expression after treatment with losartan, spironolactone, and a combination 
therapy of losartan and spironolactone in a type 2 diabetes rat model. The 
spironolactone treated group and combination group exhibited marked 
reduction of VEGF mRNA expression compared to the diabetic control group. 
The immunohistochemical expression of VEGF showed marked decreases in 
the losartan treated group and in the combination group, but the 
spironolactone treated group was not significantly different from the diabetic 
control group. There was a tendency toward decreased VEGF expression in 
the combination treatment group according to the results of western blot 
analysis, but this difference was not statistically significant. These data could 
partially suggested that combination therapy with losartan and spironolactone 
may effect on diabetic nephropathy by reducing VEGF expression. But, the 
discrepancies between the results of mRNA expression and protein levels 
may be a limitation of the interpretation of our data. This difference may be 
explained that analyses for VEGF may be due to varying tissue components. 
Besides we examined only glomeruli by immunohistochemical staining, we 
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could not isolate glomeruli from with tubules and interstitial tissue in mRNA 
and Western blot analysis. 
Activation of the tissue renin-angiotensin system (RAS) causes 
increased production of reactive oxygen species (ROS) through activation of 
the NADPH oxidase enzymatic complex in numerous tissues, including renal 
tissue. Angiotensin and other cytokines can cause diabetic nephropathy 
through inflammatory mechanisms (43-44). Blockade of the RAS may have 
protective effects against diabetic nephropathy through anti-oxidative and 
anti-inflammatory mechanisms (29-30). In our study, only a combination 
therapy of losartan and spironolactone reduced levels of the 
malonyldialdehyde (MDA)-oxidative stress marker. MCP-1, an 
inflammatory marker, also tended to decrease only in rats treated with both 
therapies. These results may indirectly explain that spironolactone and 
losartan combination therapy could be helpful for the treatment of diabetic 
nephropathy. 
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V. Conclusion 
In conclusion, we suggested that a combination treatment including 
both angiotensin receptor blocker and aldosterone receptor blocker may 
decrease proteinuria in patients with diabetic nephropathy by reducing VEGF 
expression, TGF-β and type IV collagen expression. Also, we proposed 
that combination treatment may be beneficial for diabetic nephropathy 
through anti-inflammatory and anti-oxidative mechanisms.  
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 국문요약  
Effects of spironolactone, losartan and combination therapy 
on diabetic nephropathy in OLETF rats 
 
Myoung Sook Shim 
Dept. of Medical Science 
The Graduate School 
Yonsei University 
 
연구배경: 현재까지 알도스테론수용체억제제가 제2형 당뇨병에서 항염증작용 
및 항산화작용을 통하여 알부민뇨를 감소시켰다는 보고는 있으나 
혈관내피성장인자에 대한 영향에 대해서는 아직 밝혀지지 않은 상태이다. 본 
연구에서는 제2형 당뇨병 쥐 모델에서 안지오텐신수용체억제제인 losartan 또는 
알도스테론수용체억제제인 spironolactone을 처리하였을 경우 또한 이들 약제를 
동시에 투여하였을 경우 혈관내피성장인자를 억제하여 알부민뇨를 감소시킬 수 
있는지 알아보고자 하였다.  
방법: 33마리의 OLETF쥐를 생후 5주에 분양 받아 25주부터 50주까지 4군으로 
나누어 실험하였다. 각군은 당뇨병 대조군인 CO군 (N=5), spironolactone 처치 
당뇨병군, SPR군(N=10), losartan 처치 당뇨병군, LO군(N=9), 그리고 
spironolactone과 losartan을 동시에 투여한 당뇨병군, COM군(N=9)으로 
구성하여 실험을 진행하였다. 생후 15주, 25주, 30주, 50주에 24시간 소변을 모아 
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알부민-크레아티닌 비와 24시간 소변 단백량을 측정하였다. 생후 50주에 
실험쥐들을 희생시킨 후 양측 신장을 보관하여 VEGF, TGF-β, type IV 
collagen의 mRNA 측정 및 western blot을 시행하였다.  
결과: 생후 50주에 비교한 24시간 소변 단백량 및 알부민-크레아티닌 비는 
CO군에 비하여 LO군이나 COM군에서 현저하게 감소되었으나 SPR군에서는 
CO군과 차이가 없었다. 신장사구체에서 VEGF mRNA 발현은 CO군에 비하여 
SPR군과 COM군에서 의미 있게 감소하였다. Western blot에서는 COM군에서만 
감소하는 양상을 보였으나 통계적으로는 차이가 없었다. VEGF에 대한 
면역조직화학염색 결과 CO군에 비하여 LO군과 COM군에서는 감소하였지만 
SPR군에서는 큰 차이를 보이지 않았다. TGF-β와 type IV collagen의 발현은 
SPR군과 COM군에서 의미 있게 감소하였고 MDA는 COM군에서만 의미 있게 
감소하였다. 
결론: 당뇨병성 신증 치료에 있어 알도스테론수용체억제제와 
안지오텐신수용체억제제를 동시에 투여하는 것은 VEGF 발현 및 TGF-β, type 
IV collagen, 산화 스트레스를 감소시켜 당뇨병선 신증의 치료에 효과가 있을 
것으로 생각된다. 
--------------------------------------------- 
중심 단어:  알도스테론수용체억제제, 안지오텐신수용체억제제, 당뇨병성 신증, 
혈관내피성장인자  
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